The Parkwalk Opportunities EIS Fund is open all year round and offers advisers and clients a unique gateway to invest into university spinouts. Operating under the Enterprise Investment Scheme (EIS), the fund provides tax reliefs to UK investors while supporting early-stage innovation emerging from world-leading universities.
Since 2009, Parkwalk have backed cutting-edge innovation across deep tech and life sciences, including sectors such as quantum computing, artificial intelligence, digital health, and biotechnology. They have established themselves as the UK’s largest growth EIS fund manager, with a strong track record of backing transformative technologies. The firm has invested in over 180 companies and boasts over 70 exits to date.
The EISis designed to meet the needs of financial advisers and their clients seeking access to tax-efficient investments with long-term growth potential.
The Parkwalk Opportunities EIS Fund has:
· A £25,000 minimum subscription
· Targeted deployment time of 12-18 months
· A diverse portfolio of eight companies minimum per investor
Parkwalk’s investment strategy has a defined focus on UK university spinouts, offers diverse asset allocation to mitigate risks, and provides strong deal flow via University Funds, existing portfolio and key relationships.
Of course, as advisers will know, due to the potential for losses, the Financial Conduct Authority (FCA) considers such EIS investment to be high risk. EIS investments should therefore be viewed as longer-term investments and may be more difficult to realise than an investment in listed securities. Tax reliefs are dependent on investee companies maintaining EIS qualifying status and investors’ individual circumstances. Current tax rules are subject to change.
